Chromatographic purity does not constitute a toxicological safety profile.
In analytical peptide biochemistry, chromatographic purity is routinely conflated with biological safety. Empirical forensic testing of gray-market peptide supply chains reveals a consistent pattern: nominal product labeling frequently diverges from true vial composition, and non-target impurities remain uncharacterized.
Forensic analysis of secondary market formulations
In August 2026, the Australian Broadcasting Corporation (ABC) published analytical findings examining counterfeit and gray-market formulations of retatrutide distributed via online storefronts, following clinical admissions for acute toxic hepatitis and hepatic failure:
- Quantitative variance
- Of eighteen independent samples subjected to quantitative assay, only one conformed to its nominal label strength. The remaining seventeen demonstrated significant over- or under-concentration.
- Compositional discrepancy
- Target peptide mass accounted for approximately 10% of total solids in evaluated vials; the remaining 90% comprised uncharacterized secondary compounds and excipients.
- Documented clinical morbidity
- Hospitalized patients presented with severe, acute hepatocellular injury requiring tertiary hepatology and liver transplant intervention.
- Investigational status
- Retatrutide remains an investigational multi-receptor agonist without global marketing authorization. Consequently, any retail formulation marketed for administration is illicit, unvalidated, and non-compliant by definition.
| Composition of a typical unregulated vial | |
|---|---|
| Target peptide (~10%) | Nominal active compound |
| Unidentified remainder (~90%) | Synthesis impurities, counterions, residual solvents |
What identity and purity assays do not tell you
Standard commercial Certificates of Analysis generally report results from two analytical methodologies: reverse-phase high-performance liquid chromatography (RP-HPLC) for relative peak area integration, and electrospray ionization mass spectrometry (ESI-MS) for molecular mass verification.
“All that they know from this testing is that there is some retatrutide in their vials. It doesn’t actually tell them if there’s any other contaminants or any other drugs or medications that could be mixed with them.”
Dr Marie Sinclair, transplant hepatologist, Austin Health, quoted by the ABC
“We had two different laboratories help us with that and did a very extensive analysis of components in these vials, and even with extensive testing we don’t have the full picture.”
Dr Marie Sinclair, on forensic screening of vials associated with acute clinical toxicity
These methodological parameters must be evaluated with scientific precision. An optical RP-HPLC assay coupled with single-quadrupole MS answers narrow questions: does a detectable peak elute at the anticipated retention window, and does the primary species exhibit the theoretical mass-to-charge (m/z) ratio?
Such testing remains inherently blind to:
- Bacterial endotoxins
- Pyrogenic lipopolysaccharides (LPS) requiring specialized Limulus amebocyte lysate (LAL) or recombinant Factor C (rFC) fluorometric assays.
- Heavy metal catalysts
- Residual palladium, tin, or lead scavengers undetectable without inductively coupled plasma mass spectrometry (ICP-MS).
- Residual synthesis reagents
- Trace organic solvents (e.g., trifluoroacetic acid, dichloromethane, dimethylformamide, piperidine) requiring headspace gas chromatography-mass spectrometry (GC-MS).
- Microbial and fungal bioburden
- Viable particulate contamination undetectable without specialized compendial sterility cultures.
We are not the exception to this
Lyotide Scientific provides lot-specific manufacturer CoAs to supply empirical baseline documentation for intake logging. This documentation does not confer a safety certification, nor does it clear material for in vivo applications.
- Certificate of analysis
- Empirical evidence of compound identity and relative optical purity for an individual manufacturing lot, derived under specified conditions at a specific time point.
- Exclusions
- A standard CoA is not a toxicological evaluation, sterility certification, endotoxin clearance, or validation for in vivo veterinary or human use.
- Commercial positioning
- We supply institutional and commercial enterprises strictly under a for research and development / laboratory use only (RUO) mandate.
- Internal release
- Enterprise clients are expected to subject all inbound raw materials to internal orthogonal analytical verification aligned with their specific experimental tolerances.
Related reading: clinical governance and regulatory notice and compounding regulatory landscape.
Carbonell, R., Gribbin, C., & Yu, A. (2026, August 28). New testing of black market peptides reveals dangerous dosing levels. ABC News (Australia). Read the original report. Quotations are the ABC’s; the commentary is ours.